Banco Santander Boosts Stake in Moderna

Institutional investor increases ownership in COVID-19 vaccine maker

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Banco Santander S.A., a major Spanish financial institution, has increased its stake in Moderna, Inc. (NASDAQ:MRNA) by 22.1% during the third quarter of 2025, according to a recent SEC filing. The bank now owns 215,894 shares of the biotechnology company, worth approximately $5.6 million.

Why it matters

Moderna's COVID-19 vaccine has been a major commercial success, and the company's stock has seen significant volatility as a result. Banco Santander's increased investment in the company suggests the bank's confidence in Moderna's long-term prospects, despite the stock's recent fluctuations.

The details

According to the SEC filing, Banco Santander acquired an additional 39,056 shares of Moderna during the third quarter, bringing its total ownership to 215,894 shares. This represents approximately 0.06% of Moderna's outstanding shares. The bank's increased stake in Moderna is part of a broader investment strategy, as the filing also shows the bank's holdings in other biotechnology and pharmaceutical companies.

  • Banco Santander increased its stake in Moderna during the third quarter of 2025.

The players

Banco Santander S.A.

A major Spanish financial institution and one of the largest banks in the world.

Moderna, Inc.

A biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines, including the COVID-19 vaccine.

Got photos? Submit your photos here. ›

The takeaway

Banco Santander's increased investment in Moderna suggests the bank's confidence in the company's long-term prospects, despite the stock's recent volatility. This move highlights the ongoing importance of Moderna's COVID-19 vaccine and the company's potential for future growth in the biotechnology sector.